Genomics

Dataset Information

0

Transcriptome analysis of memantine-treated Shank2 wild-type and knock-out mice


ABSTRACT: Shank2 is an excitatory postsynaptic scaffolding protein strongly implicated in autism spectrum disorders (ASD). Shank2-mutant mice with a homozygous deletion of exons 6 and 7 show decreased NMDA receptor (NMDAR) functions and autistic-like behaviors in juvenile (~postnatal day or P21) and adult (> P56) stages that are rescued by NMDAR activation. These mice, however, show an opposite change increased NMDAR functions—at ~P14, and NMDAR suppression by early and chronic memantine treatment during P7–21 prevents NMDAR hypofunction and autistic-like behaviors at juvenile (~P21) and adult (~P56) stages. To explore molecular mechanisms underlying the long-lasting effects of early memantine treatment, we performed RNA-Seq analysis of forebrains from wild-type and Shank2-mutant mice early and chronically treated with vehicle or memantine. Memantine-treated Shank2-mutant mice showed upregulations of chromatin-related genes and downregulations of mitochondria- and ribosome-related genes. In addition, vehicle-treated Shank2-mutant mice showed transcriptomic patterns that are largely opposite to those observed in ASD, as supported by the expression patterns of ASD-risk/related genes and cell-type-specific genes. These patterns, likely representing compensatory changes, were weakened by early memantine treatment. These results suggest that early chronic memantine treatment in Shank2-mutant mice alters chromatin- and mitochondria/ribosome-related gene expressions and weakens anti-ASD transcriptomic patterns.

ORGANISM(S): Mus musculus

PROVIDER: GSE171931 | GEO | 2021/10/06

REPOSITORIES: GEO

Similar Datasets

2021-04-20 | GSE97896 | GEO
2021-04-20 | GSE82066 | GEO
2021-05-27 | GSE168211 | GEO
2022-11-02 | GSE200439 | GEO
2017-01-24 | GSE79824 | GEO
2019-02-04 | GSE122550 | GEO
2022-07-21 | GSE203249 | GEO
2019-11-12 | PXD012110 | Pride
2022-07-21 | GSE203214 | GEO
2010-05-01 | GSE20533 | GEO